trending Market Intelligence /marketintelligence/en/news-insights/trending/U14y9DJzSpVAsYn571B71w2 content esgSubNav
In This List

Zoetis CEO to step down in December; replacement named from within ranks

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Zoetis CEO to step down in December; replacement named from within ranks

Juan Ramón Alaix is retiring as Zoetis Inc.'s CEO, effective Dec. 31, but will act as an adviser on the leadership transition till the end of 2020.

Kristin Peck, who has been a member of the Zoetis executive leadership team since the company's formation in 2012, will be replacing Alaix as the company's CEO.

Peck works as Zoetis' executive vice president and is group president of U.S. operations, business development and strategy. She will retain this position until Jan. 1, 2020.

However, she will be joining the board of directors immediately.

Since 2015, Peck has overseen the launch of Zoetis products like Simparica and Cytopoint for dogs. Peck has also played a key role in establishing more data and insight-driven sales and marketing functions for the benefit of U.S. customers, the company said in an Oct. 3 press release.

Previously, Peck acted as Pfizer Inc.'s executive vice president of worldwide business development and innovation and was responsible for evaluating strategic alternatives for Pfizer's Animal Health and Nutrition businesses.